Nordicus Partners Corp · OTC:NORD
Nordicus Partners — Investor Presentation (April 2025)
12 slides from Nordicus Partners's investor presentation, Apr 1, 2025
Slide 1: Transforming Oral Leukoplakia Treatment
Bio 2 Convert TRANSFORMING ORAL LEUKOPLAKIA TREATMENT Aimed at minimizing or removing oral leukoplakia lesions & reducing the risk of patients developing oral cancer from it
Slide 2: Who We Are
Who We Are About Us (© Bio-Convert A/S is a Danish preclinical biotech company founded in 2018 by the experienced life science headhunter Mr. Christian Hill-Madsen. Originally founded as a life sclence management company, under the name life Science Power House, (© In 2023, after partnering with ren
Slide 3: Understanding Oral Leukoplakia
Bio @ Convert Understanding Oral Leukoplakia © Oral leukoplakia is characterized by white patches or plaques in ‘© Types of Oral Leukoplakia (OLK) & Cancer Risk NOFeIAL:Hourte the mouth, and when accompanied by dysplasia (abnormal cell OLK is classified into homogeneous (smooth, white, growth), it b
Slide 4: Dysplasia: A Key Predictor of OLK Progression
Bio @ Convert Dysplasia: A Key Predictor of OLK Progression © Normal cells may undergo changes that could lead to cancer via dysplasia. © The degree of dysplasia is the primary predictor of OLK’s cancerous potential and is classified using WHO's three-tier system: 1uceat Squamous Celt Carcinoma"* *
Slide 5: Key Challenges and Current Limitations
Bio @ Convert Key Challenges and Current Limitations Product Formulation Issues: A key challenge in oral drug delivery is ensuring that the active ingredient remains in the mouth long enough to be effective. Previous product developments have struggled with insufficient formulations, adhering to the
Slide 6: QR-02: A Breakthrough in Oral Leukoplakia Treatment
Bio @ Convert QR-02: A Breakthrough in Oral Leukoplakia Treatment PROLONGED MUCOADHESION FOR IMPROVED DRUG DELIVERY QR-02 is a novel mucoadhesive oral formulation that adheres to the oral cavity for 12:24 hours ~ a major advancement over current treatments ~ enhancing drug efficacy and patient outco
Slide 7: Bio-Convert's R&D Pipeline
Bio-Convert’s R&D Pipeline Product Disease Area Pre-Clinical Development | oral Leutopiakis | QR-02 4.2025 Bio-Convert expects to complete CMC. developmentin Q4 2025 cmc development cmc development Bio-Convert has by the Danish Medicine ‘Agency received exemption from conducting additional animal to
Slide 8: Domestic & International Partners
Bio @ Convert Domestic & International Partners Bio-Convert collaborates with leading domestic and international experts across various aspects of drug development, reinforcing our commitment to creating the top medical treatment for oral leukoplakia patients worldwide.
Slide 9: Oral Leukoplakia & Cancer: Prevalence, Progression, & Treatment
Bio @ Convert Oral Leukoplakia & Cancer: Prevalence, Progression, & Treatment Oral Leukoplakia has a global 5-year survival rate drops prevalence of 2-497? to 50- 66% once a person develops oral cancer? 10-23% of the times OLK } @ Cancers of the oral cavity will develop into oral account for approx.
Slide 10: Market Statistics
Market Statistics Oncology Drugs - Market Share’® Asia Paci atin America Middle East & Arica Bio @ Convert Global Oral Cancer Treatment (Billion USD)"” 400 200 100 00 2020 2021 2022 —«2028-~=«024~—«2025-~=«OS:=«C«OAT «== 029~—«2030, = CAGR of 5.3% from 2020-2030 10
Slide 11: Thank you!
Thank you! Do you have any questions? info@bio-convert.com +45 42 90 17 33 Dyrehavevej 3B G/F DK-2930 Klampenborg Denmark www.bio-convert.com Bio @ Convert "1
Slide 12: List of References
List of References ‘Sous, H, Vila A, Alhadlag, M.A. hed, K., Veluppila S.,TeisterN., Monreal, A. V., Vacharotayangul, P., Lodolo, M.& Woo, 5:8. (2021): Imiquimod forthe treatment of oral leukoplakia: A two-center fetrospective study, Oral Dis 2024 Jul 15. doi: 10.11 11/ed.18089, htps:Zpubmed.ocbi.ri
Nordicus Partners — Investor Presentation (April 2025) on 6ix